3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
2
Endocrine
2
Thoracic
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
5
Thyroid Carcinoma, Anaplastic
1
Thyroid Cancer, Papillary
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasms
1
Multiple Myeloma
1
Melanoma
1
Laryngeal Neoplasms
1
Hematologic Neoplasms
1
Glioma
1
Genomic Instability
1
Gastrointestinal Neoplasms
1
Erdheim-Chester Disease
1
Colorectal Neoplasms
1
Breast Neoplasms
1
Interventions
dabrafenib
2
Trastuzumab
2
zimberelimab
1
vandetanib
1
trametinib
1
tislelizumab
1
tipifarnib
1
surufatinib
1
spartalizumab
1
sargramostim
1
cobimetinib
1
aldesleukin
1
Vemurafenib
1
Tamoxifen
1
Radiotherapy
1
PLX8394
1
Interleukin-12 Subunit p35
1
Interleukin-12
1
Gefitinib
1
Doxorubicin
1
Docetaxel
1
Cisplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Thyroid Carcinoma, Anaplastic
×
Vemurafenib
×
Thoracic
×
Clear all
NCT05768178
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled